Name: Latest research reports of CCL Products India Ltd. authored by IDBI Capital and published by - Trendlyne research reports.
Item: CCL Products India Ltd.
Rating: 3
Author: IDBI Capital

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	07 Nov 2024	Metal and Mining	IDBI Capital					Sector Update	pdf post cache	Broker Report Ferrous and Non-ferrous Metals: Sector Update IDBI Capital pdf Copy Link Share on Share on Share on Share on Alert
	07 Nov 2024	CCL Products	IDBI Capital Target	816.50	734.00	691.70 (18.04%)	Target met	Hold	pdf post cache	Broker Report CCL Products (India): Q2FY25 Result Review IDBI Capital pdf Copy Link Share on Share on Share on Share on Alert
	07 Nov 2024	NCC	IDBI Capital	237.49	380.00	308.10 (-22.92%)	60.01	Buy	pdf post cache	Broker Report NCC: Q2FY25 Result Review IDBI Capital pdf Copy Link Share on Share on Share on Share on Alert
	07 Nov 2024	Amara Raja Energy	Anand Rathi Reco Target	1057.15	1490.00	1311.25 (-19.38%)	40.94	Hold	pdf post cache	Broker Report Greater potential; upgrading to a Hold Anand Rathi Belieing our Rs5bn estimate, Amara Raja’s Q2 standalone EBITDA grew 14% y/y to Rs4.4bn due to the lower-than-expected gross margin. pdf Copy Link Share on Share on Share on Share on Alert
	07 Nov 2024	Tata Steel	Motilal Oswal Target	161.24	160.00	150.95 (6.82%)	Target met	Neutral	pdf post cache	Broker Report Robust India business growth drives EBITDA beat Motilal Oswal 2QFY25 revenue stood at INR324b (-5% YoY/-2% QoQ), in line with our estimate of INR326. The QoQ decline was due to weak realization. pdf Copy Link Share on Share on Share on Share on Alert
	07 Nov 2024	Gujarat State	Motilal Oswal Target	327.00	415.00	390.40 (-16.24%)	26.91	Neutral	pdf post cache	Broker Report EBITDA miss amid lower volumes, weaker tariff Motilal Oswal Gujarat State Petronet (GUJS)’s 2QFY25 EBITDA was 18% below our estimate at INR1.9b, as total volumes came in 13% lower than our estimate. pdf Copy Link Share on Share on Share on Share on Alert
	07 Nov 2024	Clean Science	Motilal Oswal Target	1425.70	1430.00	1483.60 (-3.90%)	Target met	Neutral	pdf post cache	Broker Report Pressure on margin continues to hurt performance Motilal Oswal Clean Science (CLEAN)’s reported EBITDA in 2QFY25 was below our estimate at INR897m (+20% YoY), with a gross margin of 62.4% (vs. 65.9% in 2QFY24). pdf Copy Link Share on Share on Share on Share on Alert
	07 Nov 2024	Alembic Pharma	Motilal Oswal Target	988.95	1110.00	1079.90 (-8.42%)	Target met	Neutral	pdf post cache	Broker Report API/India trim earnings growth Motilal Oswal Alembic Pharma’s (ALPM) 2QFY25 results came in below our estimates due to the deterioration in API business and higher operational costs. pdf Copy Link Share on Share on Share on Share on Alert
	07 Nov 2024	Aavas Financiers	Motilal Oswal Target	1806.70	1880.00	1705.90 (5.91%)	Target met	Neutral	pdf post cache	Broker Report Disbursements weak; NIM compression continues Motilal Oswal AAVAS Financiers (AAVAS)’s 2QFY25 PAT grew 22% YoY to ~INR1.48b (in line). 1HFY25 PAT grew 18% YoY to ~INR2.74b. pdf Copy Link Share on Share on Share on Share on Alert
	07 Nov 2024	Trent	Motilal Oswal Target	5559.00	8200.00	6505.50 (-14.55%)	47.51	Buy	pdf post cache	Broker Report Robust growth, albeit weaker than lofty expectations on store consolidation Motilal Oswal Trent Ltd (TRENT) continued to buck the weak consumer sentiment trends, delivering robust ~40% YoY revenue (though weaker than 50%+ YoY in the past few quarters) and 46% YoY PAT growth in 2Q. pdf Copy Link Share on Share on Share on Share on Alert
more loading

New Research Reports

Latest stock research reports with share price targets forecast, buy, hold, and sell recommendations along with upside. Search by company or broker name.

Ferrous and Non-ferrous Metals: Sector Update

CCL Products (India): Q2FY25 Result Review

NCC: Q2FY25 Result Review

Greater potential; upgrading to a Hold

Robust India business growth drives EBITDA beat

EBITDA miss amid lower volumes, weaker tariff

Pressure on margin continues to hurt performance

API/India trim earnings growth

Disbursements weak; NIM compression continues

Robust growth, albeit weaker than lofty expectations on store consolidation

Advisor Screeners